Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

about

Advanced alveolar soft part sarcoma responds to apatinib.The role of Cediranib in ovarian cancer.

P2860

Q41473058-F233362B-8D5C-49F7-AD4A-7AC999377537 Q49966031-B4961670-E4E5-459C-B906-B1A529844DB8

P2860

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

Item

http://www.wikidata.org/entity/Q39036230

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@nl

type

Item

label

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@nl

prefLabel

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@nl

P1476

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

@en

P2093

Alex McCormick

http://www.w3.org/2001/XMLSchema#string

Eric Masson

http://www.w3.org/2001/XMLSchema#string

Jianguo Li

http://www.w3.org/2001/XMLSchema#string

Weifeng Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.

Interaction of common azole antifungals with P glycoprotein

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.

P2888

s40262-016-0488-y

P304

689-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-016-0488-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27943222

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

about

P2860

P2860

Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698